Precigen, Inc. (NASDAQ:PGEN) Shares Bought by Iridian Asset Management LLC CT

Iridian Asset Management LLC CT boosted its stake in Precigen, Inc. (NASDAQ:PGEN - Free Report) by 38.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 5,241,922 shares of the biotechnology company's stock after purchasing an additional 1,465,962 shares during the period. Precigen makes up approximately 1.6% of Iridian Asset Management LLC CT's holdings, making the stock its 21st largest position. Iridian Asset Management LLC CT owned about 1.79% of Precigen worth $5,871,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Traphagen Investment Advisors LLC purchased a new stake in Precigen during the third quarter valued at approximately $29,000. Stifel Financial Corp increased its stake in shares of Precigen by 94.9% during the third quarter. Stifel Financial Corp now owns 32,200 shares of the biotechnology company's stock valued at $30,000 after buying an additional 15,680 shares during the period. SG Americas Securities LLC grew its holdings in Precigen by 44.2% during the 3rd quarter. SG Americas Securities LLC now owns 45,063 shares of the biotechnology company's stock worth $43,000 after acquiring an additional 13,823 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its position in Precigen by 86.6% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 55,337 shares of the biotechnology company's stock valued at $52,000 after purchasing an additional 25,681 shares during the period. Finally, AQR Capital Management LLC raised its holdings in shares of Precigen by 56.7% in the 2nd quarter. AQR Capital Management LLC now owns 50,002 shares of the biotechnology company's stock valued at $79,000 after purchasing an additional 18,097 shares in the last quarter. 33.51% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the stock. HC Wainwright reiterated a "buy" rating and set a $6.00 price objective (up from $4.00) on shares of Precigen in a research note on Thursday, January 23rd. JMP Securities reissued a "market outperform" rating and issued a $5.00 price target on shares of Precigen in a research report on Tuesday, January 14th. Two equities research analysts have rated the stock with a sell rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $7.00.

Precigen Stock Performance

Shares of NASDAQ PGEN traded down $0.11 during midday trading on Tuesday, reaching $1.67. 1,484,819 shares of the stock were exchanged, compared to its average volume of 2,127,835. Precigen, Inc. has a twelve month low of $0.65 and a twelve month high of $1.93. The stock has a market capitalization of $489.09 million, a P/E ratio of -3.03 and a beta of 1.66. The company has a 50 day simple moving average of $1.07 and a 200 day simple moving average of $1.03.

Precigen Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.